Hematologic Malignancies
News
Baseline stress signals need for psychological help in CLL
Be on the lookout for cancer-specific stress when treating chronic lymphocytic leukemia.
Best Practices
Treatment and Management of Multiple Myeloma
A panel discussion of the challenges and standards of care for managing patients with multiple myeloma.
Conference Coverage
Getting hematologic cancer drugs on the fast track
In 2017, the FDA approved 17 agents for new or expanded indications for hematologic malignancies, including one agent for anaplastic large cell...
News
Meningococcal Arthritis Masking as Possible Myeloma
Clinicians reveal the importance of screening for an underlying impaired immune response when patients present with rare symptoms.
News
Triple therapy ups response in refractory mantle cell lymphoma
The results show that triple therapy with ibrutinib, lenalidomide, and rituximab should be evaluated in a randomized controlled trial.
Article
Rituximab Still Proves Safe Long Term
Researchers examine the long-term effects and safety of patients’ brains and autoimmune systems while receiving treatment with rituximab.
News
CLL drug in limited supply outside U.S.
Patients outside the United States will be able to access the drug only through compassionate use programs.
News
Continue to opt for HDT/ASCT for multiple myeloma
A systematic review and meta-analysis confirms that HDT/ASCT is still the best option for newly-diagnosed multiple myeloma.
News
Higher Risk of Secondary Cancers for Patients With Mycosis Fungoides
According to a 2-decade-old study, patients with mycosis fungoides have a higher risk of developing secondary solid tumors based on patient...
Conference Coverage
Late-breaking abstracts highlight treatment advances in CLL, myeloma, and more
ASH President Kenneth C. Anderson, MD, and ASH Secretary Robert A. Brodsky, MD, gave a preview of four practice-changing studies.